FDA Permits Expanded Access for daraxonrasib, Experimental Pancreatic Cancer Drug Available for Treatment Use in Certain Patients

The U.S. Food and Drug Administration (FDA) said on May 1 that it had issued a “safe to proceed” letter to Revolution Medicines, permitting the company to initiate an expanded access treatment protocol for the experimental pancreatic cancer drug daraxonrasib. This arrangement applies to patients with metastatic pancreatic ductal adenocarcinoma who have previously received treatment.

Expanded access is not the same as a drug being approved for marketing. Rather, in serious or life-threatening diseases, it allows eligible patients who lack suitable treatment options to apply, through physician and drug-company procedures, to use a drug that is still under investigation. The FDA said such requests must be submitted to the drug sponsor by a U.S.-licensed physician on behalf of an eligible patient.

Daraxonrasib, also known as RMC-6236, is an experimental inhibitor targeting the RAS pathway. Mutations in RAS proteins are associated with growth signaling in multiple cancers, and the FDA noted in its announcement that most pancreatic cancer tumors carry RAS mutations; therefore, whether this pathway can be interfered with effectively and tolerably has long been an important question in pancreatic cancer drug development.

The FDA’s handling timeline in this case was quite rapid: the announcement said the FDA received Revolution Medicines’ expanded access request on April 28 and signed the letter permitting it to proceed on April 30. The rapid regulatory response shows that authorities are willing to accelerate pathways for patient access to experimental treatments in disease areas with high unmet medical need.

However, the news should still be interpreted cautiously. The FDA announcement did not provide new clinical trial data, patient numbers, response rates, or details on adverse events; the opening of an expanded access protocol also does not mean the drug has been proven to improve survival or become a standard treatment. Whether a patient is suitable for use still needs to be assessed by the treating physician based on disease status, prior treatment, potential risks, and the investigational nature of the drug.

In terms of regulatory progress, daraxonrasib had previously received FDA breakthrough therapy designation and orphan drug designation. The FDA also noted that the drug has been associated with the “National Priority Review Voucher” pilot pathway, and Revolution Medicines had said it planned to submit a new drug application through this route. The next key question will be whether the formal application data can support determinations of efficacy, safety, and the applicable patient population.